Faculty Bibliography

Afferent baroreflex failure occurs in the genetic disorder familial dysautonomia (FD) and in patients with acquired lesions of the afferent baroreflex pathways. Afferent baroreflex failure is characterized by extremely labile blood pressure, with paroxysmal hypertension due to unrestrained norepinephrine release, which may result in targetorgan damage. These hypertensive episodes are traditionally managed with the alpha-2-receptor agonist clonidine, but this produces profound hypotension, fatigue and rebound hypertension. Carbidopa is a competitive reversible inhibitor of the enzyme dopa-decarboxylase that does not cross the blood brain barrier. Here we examined the effect of carbidopa on norepinephrine production and blood pressure variability in 12 patients with FD and 3 with acquired afferent baroreflex failure. Patients underwent a 24-h urine collection and simultaneous ambulatory blood pressure monitoring at baseline (pretreatment) and while taking carbidopa. Catecholamine excretion was measured using high performance liquid chromatography (HPLC). Blood pressure variability was calculated from the standard deviation of blood pressure values captured at 20-min intervals during waking hours. Mean dose of carbidopa was 500 mg per day. Compared to baseline, carbidopa significantly reduced norepinephrine excretion (32 +/- 9 vs. 12 +/- 1 lg/gCr, p<0.001) and blood pressure variability (25 +/- 3 vs. 19 +/- 3 mmHg, p<0.03). Carbidopa reduced the highest blood pressure value captured on ambulatory monitoring from 175 +/- 6 to 155 +/- 9 mmHg (p<0.03), while the lowest captured blood pressure values were similar pre and post-treatment. Carbidopa inhibits the downstream production of norepinephrine and is a novel approach to treating paroxysmal hypertension in patients with genetic or acquired afferent baroreflex failure

Familial dysautonomia (FD) is caused by a splicing error in the IKBKAP gene that encodes human Elongator protein-1 (ELP-1). In these patients, exon 20 is frequently skipped duringmRNA splicing, but cells retain the ability to produce a lowlevel of normal (wild-type) IKBKAPmRNAand normal protein. Phosphatidylserine (PS, Sharp-thought), an acidic phospholipid, has been shown to raise elongator protein-1 levels by increasing IKBKAPtranscription in fibroblast cell-lines derived fromFD patients and, more recently, in a mouse model of FD. Given that PS is available over the counter, weconducted a study to determinewhether PS raises IKBKAP gene expression in patients with FD. We enrolled 7 patients with FD, 16-23 years old, in an open-label titration protocol. Patients were examined at baseline (visit 1), after 2 months of taking 300 mg/day (visit 2) and again after 2 months of taking 600 mg/day of PS(visit 3).Bloodwas taken at each visit. Sampleswere de-identified and investigators blinded to the sample identity. Blood was treated with Tri- Reagent, and RNA extracted according to manufacturers specifications. Quantitative polymerase chain reaction (qPCR) was performed to measure the level of normal IKBKAPmRNA. PSwas well tolerated and there were no adverse events or unexpected laboratory abnormalities. After 2 months of taking 300 mg of PS per day, there was a trend for IKBKAP mRNA levels to increase. After 2 months of 600 mg of PS per day, IKBKAPmRNAexpression increased between 2 and 8 fold in all but one patient (p<0.01). Our results indicate that PS safely raises wild-type IKBKAP mRNA levels in blood from patients with FD, opening an exciting potential therapeutic path for treatment. Clinical trials to determine whether restoring Elongator protein 1 levels impacts the phenotype are underway

BACKGROUND: Hereditary sensory and autonomic neuropathy type III features marked ataxic gait that progressively worsens over time. We assessed whether proprioceptive disturbances can explain the ataxia. METHODS: Proprioception at the knee joint was assessed using passive joint angle matching in 18 patients and 14 age-matched controls; 5 patients with cerebellar ataxia were also studied. Ataxia was quantified using the Brief Ataxia Rating Score, which ranged from 7 to 26 of 30. RESULTS: Neuropathy patients performed poorly in judging joint position: mean absolute error was 8.7 degrees +/- 1.0 degrees , and the range was very wide (2.8 degrees -18.1 degrees ); conversely, absolute error was only 2.7 degrees +/- 0.3 degrees (1.6 degrees -5.5 degrees ) in the controls and 3.0 degrees +/- 0.2 degrees (2.1 degrees -3.4 degrees ) in the cerebellar patients. This error was positively correlated to the degree of ataxia in the neuropathy patients but not the cerebellar patients. CONCLUSIONS: These results suggest that poor proprioceptive acuity at the knee joint is a major contributor to the ataxic gait associated with hereditary sensory and autonomic neuropathy type III.

OBJECTIVE: The purpose of this study was to determine whether carbidopa (Lodosyn), an inhibitor of dopa-decarboxylase that blocks the synthesis of dopamine outside the brain, is an effective antiemetic in patients with familial dysautonomia (FD) and hyperdopaminergic nausea/retching/vomiting attacks. METHODS: We enrolled 12 patients with FD in an open-label titration and treatment study to assess the safety of carbidopa. We then conducted a randomized, double-blind, placebo-controlled, crossover study to evaluate its antiemetic efficacy. RESULTS: Previous fundoplication surgery in each patient studied prevented vomiting, but all of the subjects experienced severe cyclical nausea and uncontrollable retching that was refractory to standard treatments. Carbidopa at an average daily dose of 480 mg (range 325-600 mg/day) was well tolerated. In the double-blind phase, patients experienced significantly less nausea and retching while on carbidopa than on placebo (p < 0.03 and p < 0.02, respectively). Twenty-four-hour urinary dopamine excretion was significantly lower while on carbidopa (147 +/- 32 microg/gCr) than while on placebo (222 +/- 41microg/gCr, p < 0.05). CONCLUSIONS: Carbidopa is a safe and effective antiemetic in patients with FD, likely by reducing the formation of dopamine outside the brain. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that carbidopa is effective in reducing nausea/retching/vomiting in patients with FD.

Takotsubo cardiomyopathy is an acute reversible cardiac dysfunction syndrome associated with high circulating catecholamine levels. Our objective was to investigate whether abnormal cardiovascular control might play a role in the pathophysiology. We studied autonomic cardiovascular reflexes in 10 women who had takotsubo (33+/-7 months after being hospitalized) and 10 age/BMI matched healthy women. In the women with takotsubo, indices of vagal modulation of heart rate induced by respiration were uniformly reduced (expiratory:inspiratory ratio: p<0.01, pnn50%: p<0.02, rMSSD: p<0.03). Cognitive (stroop test: p<0.03) and emotional arousal (event recall: p<0.05) produced exaggerated pressor responses, without detectable ECG changes. Pressor responses to hemodynamic stimuli were also amplified (Valsalva SBP overshoot: p<0.05). Takotsubo women had increased BP variability in the short-term (St. Dev. SBP: p<0.01). Ambulatory recordings captured an exaggerated morning surge in SBP after awakening from sleep (p<0.05). Cardiovagal baroreflex gain was significantly lower in the takotsubo women (sequence analysis: p<0.01, regression method: p<0.001, transfer function gain: p<0.001). Women with takotsubo have heightened sympathetic responsiveness, labile BP and reduced vagal modulation of the heart. This shift in sympathovagal balance could play a role in the pathophysiology

OBJECTIVE: To determine if carbidopa, a dopa-decarboxylase inhibitor that blocks the formation of dopamine outside the brain, is an effective antiemetic in patients with familial dysautonomia (FD). BACKGROUND: Patients with FD, an hereditary neuropathy that affects the development of sensory neurons of the baroreflex, are unable to restrain the release of catecholamines from sympathetic nerve terminals at times of stress. Recurrent attacks of nausea, retching and vomiting, associated with high levels of circulating dopamine are a disabling feature of the disease for which there is no effective treatment. DESIGN/METHODS: We enrolled 12 patients with FD in an open-label titration and treatment study to assess the safety of carbidopa, an inhibitor of the enzyme dopa decarboxylase that does not cross the blood brain barrier. We then conducted a randomized, double-blind, placebo-controlled, crossover study to evaluate its antiemetic efficacy. RESULTS: All patients experienced severe cyclical nausea and uncontrollable retching that was refractory to standard treatments. Carbidopa at an average daily dose of 480 mg (range 325 to 600 mg/day) was well tolerated. In the double-blind phase, patients experienced significantly less nausea and retching while on carbidopa than on placebo (p<0.03 and p<0.02. respectively). Twenty-four hour urinary dopamine excretion was significantly lower while on carbidopa (147+/-32 ug/g crt) than while on placebo (222+/-41 ug/g crt, p<0.05). CONCLUSIONS: Carbidopa appears to be a safe and effective antiemetic in patients with FD likely by reducing the formation of dopamine outside the brain. Larger trials are warranted

Familial dysautonomia (Riley-Day syndrome) is an hereditary sensory and autonomic neuropathy (HSAN type III), expressed at birth, that is associated with reduced pain and temperature sensibilities and absent baroreflexes, causing orthostatic hypotension as well as labile blood pressure that increases markedly during emotional excitement. Given the apparent absence of functional baroreceptor afferents, we tested the hypothesis that the normal cardiac-locked bursts of muscle sympathetic nerve activity (MSNA) are absent in patients with familial dysautonomia. Tungsten microelectrodes were inserted percutaneously into muscle or cutaneous fascicles of the common peroneal nerve in 12 patients with familial dysautonomia. Spontaneous bursts of MSNA were absent in all patients, but in five patients we found evidence of tonically firing sympathetic neurones, with no cardiac rhythmicity, that increased their spontaneous discharge during emotional arousal but not during a manoeuvre that unloads the baroreceptors. Conversely, skin sympathetic nerve activity (SSNA), recorded in four patients, appeared normal. We conclude that the loss of phasic bursts of MSNA and the loss of baroreflex modulation of muscle vasoconstrictor drive contributes to the poor control of blood pressure in familial dysautonomia, and that the increase in tonic firing of muscle vasoconstrictor neurones contributes to the increase in blood pressure during emotional excitement.

GOALS: : To analyze the neurochemical profile during the recurrent attacks of nausea and vomiting in patients with Riley-day syndrome. BACKGROUND: : One of the most disabling features of patients with Riley-day syndrome are recurrent attacks of severe nausea/retching/vomiting accompanied by hypertension, tachycardia, and skin flushing, usually triggered by emotional or other stresses. STUDY: : We monitored blood pressure and heart rate and measured plasma catecholamines during typical dysautonomic crises triggered by emotionally charged situations. For comparison, measurements were repeated at follow-up after the symptoms had resolved and the patients were feeling calm and well. RESULTS: : During a typical attack, patients were hypertensive and tachycardic. In all patients, circulating levels of norepinephrine (P<0.002) and dopamine (P<0.007) increased significantly. CONCLUSIONS: : Activation of dopamine receptors in the chemoreceptor trigger zone may explain the cyclic nausea/retching/vomiting of patients with Riley-day syndrome.

Riley Day syndrome, commonly referred to as familial dysautonomia (FD), is a genetic disease with extremely labile blood pressure owing to baroreflex deafferenation. Chronic renal disease is very frequent in these patients and was attributed to recurrent arterial hypotension and renal hypoperfusion. Aggressive treatment of hypotension, however, has not reduced its prevalence. We evaluated the frequency of kidney malformations as well as the impact of hypertension, hypotension and blood pressure variability on the severity of renal impairment. We also investigated the effect of fludrocortisone treatment on the progression of renal disease. Patients with FD appeared to have an increased incidence of hydronephrosis/reflux and patterning defects. Patients <4 years old had hypertension and normal estimated glomerular filtration rates (eGFR). Patients with more severe hypertension and greater variability in their blood pressure had worse renal function (both, P<0.01). In contrast, there was no relationship between eGFR and the lowest blood pressure recorded during upright tilt. The progression of renal disease was faster in patients receiving fludrocortisone (P<0.02). Hypertension precedes kidney disease in these patients. Moreover, increased blood pressure variability as well as mineralocorticoid treatment accelerate the progression of renal disease. No association was found between hypotension and renal disease in patients with FD.Journal of Human Hypertension advance online publication, 1 December 2011; doi:10.1038/jhh.2011.107

Familial dysautonomia (FD) is a rare hereditary disorder caused by mutations within the gene that encodes for I-kappa-B kinase complex associated protein (IKAP). A deficiency of IKAP affects the development of primary sensory neurons including those carrying baroreflex afferent volleys, a feature that explains their characteristic sensory loss and labile blood pressure. This review describes the history, the genotype of FD and the unusual cardiovascular autonomic phenotype of these patients. We outline the main consequences of a failure to receive information from arterial baroreceptors, including the characteristic "autonomic storms" and severe end-organ target damage.